Modifications of Gut Microbiota Are Associated with the Severity of IgA Nephropathy in the Chinese Population
Overview
Pharmacology
Affiliations
Immunoglobulin A nephropathy (IgAN) is a common glomerular disease. The pathogenesis of IgAN is associated with dysregulated intestinal mucosal immunity. However, whether gut microbial modifications play a role in IgAN remains unclear. Blood and faecal samples were collected from 52 patients with IgAN and 25 healthy controls (HCs). The gut microbiome was analysed using the 16S ribosomal RNA gene. The levels of galactose-deficient IgA1 (Gd-IgA1), soluble cluster of differentiation 14 (sCD14), lipopolysaccharide binding protein (LBP), intercellular adhesion molecule-1 (ICAM-1), tumour necrosis factor α (TNF-α), interleukin-1, and C-reactive protein were quantified. Substantial differences in the gut microbiota were identified between patients with IgAN and HCs (P < 0.05). Bacteroides and Escherichia-Shigella levels were significantly higher in patients with IgAN than in HCs, while Bifidobacterium and Blautia spp. Levels were lower. Higher proportions of Escherichia-Shigella and lower proportions of Bifidobacterium spp. were observed in patients with IgAN with high urine RBC count (≥10/HP) and proteinuria (≥1 g/24 h) levels. Correlation analysis was used to assess the association between gut microbiota and biomarkers in patients with IgAN. The results showed that Prevotella 7 levels were negatively correlated with Gd-IgA1, LBP, sCD14, ICAM-1, and TNF-α levels, while Bifidobacterium spp. Levels presented a significant inverse relationship with LBP and Gd-IgA1. Additionally, Escherichia-Shigella levels were negatively correlated with Prevotella 7. In patients with IgAN, gut modifications were characterised by an increase in the number of pathogenic bacteria and a reduction in the levels of beneficial bacteria, suggesting that the disturbance of intestinal microflora might be important in the severity of IgAN.
Characteristics, pathogenic and therapeutic role of gut microbiota in immunoglobulin A nephropathy.
Yao K, Zheng L, Chen W, Xie Y, Liao C, Zhou T Front Immunol. 2025; 16:1438683.
PMID: 39981255 PMC: 11839611. DOI: 10.3389/fimmu.2025.1438683.
Zhang R, Tang Y, Feng X, Lu X, Zhao M, Jin J Gut Microbes. 2025; 17(1):2458184.
PMID: 39875350 PMC: 11776482. DOI: 10.1080/19490976.2025.2458184.
Wang X, Zhou X, Qiao X, Falchi M, Liu J, Zhang H Theranostics. 2025; 15(2):656-681.
PMID: 39744688 PMC: 11671385. DOI: 10.7150/thno.104631.
Causal relationship between dietary intake and IgA nephropathy: a Mendelian randomization study.
Li Y, Wan S, Liu J, Huang Y, Jiang L Front Nutr. 2024; 11:1400907.
PMID: 39285865 PMC: 11403370. DOI: 10.3389/fnut.2024.1400907.
Gut and respiratory microbiota landscapes in IgA nephropathy: a cross-sectional study.
Yuan X, Qing J, Zhi W, Wu F, Yan Y, Li Y Ren Fail. 2024; 46(2):2399749.
PMID: 39248406 PMC: 11385635. DOI: 10.1080/0886022X.2024.2399749.